impact of allelic state on os in tp53-mutant aml and hr-mds
Published 1 year ago • 63 plays • Length 2:26Download video MP4
Download video MP3
Similar videos
-
3:46
variant allele frequency in patients with sf3b1-mutated mds
-
2:12
allosct for aml with mds-related features as per the icc and who 2022 classifications
-
2:23
the significance of variant allele frequency in patients with sf3b1-mutated mds
-
2:08
hematological response to frontline treatment in lr-mds is associated with better os
-
3:10
the role of ngs in mds diagnosis
-
1:16
state of the art: mds
-
1:27
the impact of inflammation & the microenvironment in the development and progression of mds
-
3:22
performance of the aipss-mds ml model in predicting os & leukemic transformation in cmml
-
2:22:02
new variam frequency - beyond healing
-
4:28
understanding myelodysplastic syndromes (mds)
-
4:48
managing and treating mds
-
2:02
unmet needs in high-risk mds and future therapeutic strategies
-
2:58
impact of environmental factors on mds
-
1:34
perspectives on the management of low and high-risk mds
-
1:17
the curative potential of allosct in the treatment of hr-mds
-
2:17
oncogenic mutational networks in acute myeloid leukemia (aml) and myelodysplastic syndromes (mds)
-
1:02
emerging treatment options for lower- and higher-risk mds and ongoing trials
-
2:04
state-of-the-art treatment for hr-mds
-
1:00
mds: what's the impact of early diagnosis?
-
2:43
novel therapies in the future of mds treatment
-
2:16
current and future treatment approaches for hr-mds
-
2:44
bmt ctn 1506/morpho: flt3-itd variant allele frequency and mrd data